Axsome Therapeutics plans to submit a New Drug Application (NDA) to the FDA. Herriot Tabuteau is the CEO of the company.
7 reports, 3 independent
Updated Mon 00:00
Mostly repetition
- Reports
- 7
- Developments
- 2
- Repetition
- 71%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Axsome Therapeutics plans to submit a New Drug Application (NDA) to the FDA. Herriot Tabuteau is the CEO of the company.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Axsome Therapeutics plans NDA submissions to the FDA.1 source
- FDA rejected Axsome's NDA submission, requiring further study.
Keep exploring
The entities involved
-
Axsome Therapeutics
American biopharmaceutical company
Nothing else this week.
- FDA
Related events
- FDA approval supports NDA submission in Aurora.
- Takeda is seeking FDA approval for its drug ORZEYFUL.
- Syndax Pharmaceuticals has FDA-approved therapies in its pipeline and uses LinkedIn for company communication.
- NIH is funding research conducted by the National Cancer Institute (NCI) toward an FDA Investigational New Drug (IND) application.
- Argenx SE announced it is listed on Nasdaq and is seeking FDA priority review and approval.
Coverage
Newest first; wire copies grouped- manilatimes.net
- yahoo.com
- GlobeNewswireAxsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% s
- GlobeNewswireAxsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new
- Unknown outlet